| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
585.32(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.56 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
6,500 |
10,687 |
| Total Sell Value |
$48,970 |
$112,405 |
$145,240 |
$215,444 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
5 |
14 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
38,997 |
1,154,930 |
|
- |
|
| Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
8,357 |
22,541 |
|
- |
|
| Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-02-18 |
4 |
AS |
$27.84 |
$139,194 |
D/D |
(5,000) |
14,184 |
|
-3% |
|
| Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-02-18 |
4 |
OE |
$2.96 |
$14,800 |
D/D |
5,000 |
19,184 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Research Products |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
11,143 |
33,247 |
|
- |
|
| Chaubal Amol |
Chief Financial Officer |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,286 |
27,545 |
|
- |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
11,143 |
33,645 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-02-12 |
4 |
AS |
$27.17 |
$176,614 |
D/D |
(6,500) |
1,115,933 |
|
-5% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2020-02-11 |
4 |
AS |
$27.88 |
$46,476 |
D/D |
(1,667) |
49,693 |
|
-3% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-02-06 |
4 |
AS |
$27.56 |
$179,140 |
D/D |
(6,500) |
1,122,433 |
|
-3% |
|
| Madaus Martin D |
|
– • – |
2020-02-05 |
4 |
AS |
$27.65 |
$63,594 |
I/I |
(2,300) |
192,766 |
|
-2% |
|
| Madaus Martin D |
|
– • – |
2020-02-05 |
4 |
AS |
$27.70 |
$44,320 |
D/D |
(1,600) |
9,602 |
|
-2% |
|
| Madaus Martin D |
|
– • – |
2020-02-05 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
11,202 |
|
- |
|
| Madaus Martin D |
|
– • – |
2020-02-04 |
4 |
AS |
$26.95 |
$61,988 |
I/I |
(2,300) |
195,066 |
|
-5% |
|
| Madaus Martin D |
|
– • – |
2020-02-04 |
4 |
AS |
$26.52 |
$42,432 |
D/D |
(1,600) |
9,602 |
|
-5% |
|
| Madaus Martin D |
|
– • – |
2020-02-04 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
11,202 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-02-04 |
4 |
AS |
$26.71 |
$64,344 |
D/D |
(2,409) |
1,128,933 |
|
-5% |
|
| Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-02-04 |
4 |
S |
$26.71 |
$1,469 |
D/D |
(55) |
14,184 |
|
5% |
|
| Mattoon Dawn |
Sr. VP, Research Products |
• – – |
2020-02-04 |
4 |
S |
$26.71 |
$3,659 |
D/D |
(137) |
22,104 |
|
5% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-02-03 |
4 |
AS |
$27.05 |
$176,057 |
D/D |
(6,500) |
1,131,342 |
|
-7% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-01-29 |
4 |
AS |
$26.99 |
$175,407 |
D/D |
(6,500) |
1,137,842 |
|
-3% |
|
| Madaus Martin D |
|
– • – |
2020-01-23 |
4 |
AS |
$25.60 |
$58,875 |
I/I |
(2,300) |
197,366 |
|
9% |
|
| Madaus Martin D |
|
– • – |
2020-01-23 |
4 |
AS |
$24.86 |
$39,776 |
D/D |
(1,600) |
9,602 |
|
9% |
|
| Madaus Martin D |
|
– • – |
2020-01-23 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
11,202 |
|
- |
|
| Madaus Martin D |
|
– • – |
2020-01-22 |
4 |
AS |
$25.43 |
$58,484 |
I/I |
(2,300) |
199,666 |
|
6% |
|
686 Records found
|
|
Page 20 of 28 |
|
|
0.35 (2.14%) 
